Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Renal cell carcinoma (RCC) exhibits significant epigenetic modifications, including DNA methylation changes and histone modifier gene alterations.
• These epigenetic changes are implicated in RCC tumorigenesis and may correlate with an aggressive disease phenotype.
• Tumor heterogeneity presents a challenge for translating these findings into effective clinical treatments for RCC.

Purpose of the Study:

• To review recent findings on aberrant histone and DNA alterations in RCC.
• To highlight the potential of targeted chromatin remodeling therapies for managing RCC.
• To discuss the challenges in translating epigenetic insights into clinical practice for RCC.

Main Methods:

• Literature review of recent investigations into epigenetic modifications in RCC.
• Analysis of preclinical models and identified genetic/enzymatic alterations.
• Examination of identified DNA methylation changes and histone modifier mutations.

Main Results:

• Aberrant histone and DNA alterations are frequently reported in RCC.
• Specific epigenetic changes are associated with a more aggressive RCC phenotype.
• Targeted chromatin remodeling agents are under investigation for their therapeutic potential.

Conclusions:

• Epigenetic dysregulation is a critical factor in RCC pathogenesis.
• Targeted chromatin remodeling therapies offer a promising avenue for RCC treatment.
• Overcoming tumor heterogeneity is crucial for successful clinical application of these therapies.